Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Part of paid clinical trials in Jacksonville, Florida.
- Sponsor
- Mayo Clinic
- Study ID
- NCT04230304
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Daratumumab — BIOLOGICALGiven IV
- Ibrutinib — DRUGGiven PO
Study Details
This phase II trial studies how well daratumumab and ibrutinib work in treating patients with chronic lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Daratumumab is a monoclonal antibody which works with the body's immune system to destroy cancer cells. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daratumumab and ibrutinib may work better in treating patients with chronic lymphocytic leukemia compared to ibrutinib alone.
Key Dates
- Start date
- Nov 11, 2020
- Status verified
- Dec 2025
- Primary completion
- May 1, 2023
- Completion
- Feb 13, 2025
Study Design
- Enrollment
- 8 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (daratumumab, ibrutinib)Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Overall Response Rate by Cycle 7 [ Time Frame: 7 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | - |
Find similar trials in Jacksonville, FL
By research site
Related Studies
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesPHASE1 · Recruiting · Mayo Clinic · Jacksonville, Florida
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesPHASE2 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington
- CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell MalignanciesPHASE1 · Recruiting · Mayo Clinic · Rochester, Minnesota